Treace Medical Concepts, Inc.
TMCIHealthcareNASDAQMedical Devices · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Sep 3
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The $317.4M market capitalization puts TMCI squarely in small-cap range for its industry. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Market Cap
$317.4M
Beta
1.40
P/E (TTM)
—
P/E (Fwd)
-5.74
EPS (TTM)
$-0.96
EPS (Fwd)
$-0.85
ROE
-72.0%
ROA
-17.3%
Cash
$45.6M
Total Debt
$73.0M
Free CF
-$6.3M
52W Change
-34.4%
Annual Financials
Cash vs Debt
Where TMCI stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, TMCI finished 61.13% above its 150-day moving average ($2.83) and 56.16% above its 200-day moving average ($2.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TMCI overbought or oversold?
At the August 20, 2026 close, TMCI's RSI(14) was 53.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $45.6M in cash, though total debt stands at $73.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$6.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -72.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $141.8M (2022) to $212.7M (2025), reflecting a 50% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Treace Medical Concepts, Inc.'s trajectory.